StockNews.AI
ALT
StockNews.AI
2 days

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

1. Class action lawsuit initiated against Altimmune for securities violations. 2. Investors claim misleading statements regarding drug trial performances. 3. Pemvidutide's trial results failed to meet expectations, causing investor losses. 4. Investors encouraged to participate in the lawsuit by October 6, 2025. 5. Schall Law Firm specializes in securities fraud litigation for affected investors.

8m saved
Insight
Article

FAQ

Why Bearish?

Given the nature of the lawsuits and the potential liabilities faced by Altimmune, investor confidence is likely to be shaken. Historical examples such as Valeant Pharmaceuticals show significant stock downturns following litigation announcements, underscoring the relevance of legal challenges to market performance.

How important is it?

The significance of a class action lawsuit reflects a potential risk to Altimmune's financial standing, indicating the market's likely response to uncertainty. In light of the ongoing legal issues, the importance of understanding litigation risks is crucial for current and potential investors.

Why Short Term?

The immediate impact is likely as news spreads and investors react, but a longer-term recovery could depend on trial outcomes. The volatility posts lawsuits can lead to erratic stock performance in the near term until resolution.

Related Companies

VRTXISRGPTLAAMGN

LOS ANGELES, Sept. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between August 10, 2023 and June 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 6, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Altimmune touted the performance of its drug candidate Pemvidutide ahead of the results from its IMPACT Phase 2B MASH trial ("the trial"). When the results of the trial were released, they showed that Pemvidutide failed to achieved a statistically significant result in its primary endpoint. The Company treated this failure indifferently, claiming it expected a better result from its Phase 3 trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Altimmune, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alt-investors-have-opportunity-to-lead-altimmune-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302544576.html

SOURCE The Schall Law Firm

Related News